References
References1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053.WildS]]RoglicG]]GreenA&etal;Global prevalence of diabetes estimates for the year 2000 and projections for 2030.Diabetes Care2004271047-10532. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787–794.WeyerC]]BogardusC]]MottDM&etal;The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.J Clin Invest1999104787-7943. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001;44:929–945.PratleyRE]]WeyerCThe role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus.Diabetologia200144929-9454. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002;51:636–641.FinemanMS]]KodaJE]]ShenLZ&etal;The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.Metabolism200251636-6415. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199–E206.HolstJJ]]GromadaJRole of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.Am J Physiol Endocrinol Metab2004287E199-E2066. Monnier L, Colette C, Dunseath GJ, et al. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007;30:263–269.MonnierL]]ColetteC]]DunseathGJ&etal;The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes.Diabetes Care200730263-2697. Tibaldi J. The importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes. Southern Med J 2009;102:60–66.TibaldiJThe importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes.Southern Med J200910260-668. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813–819.CavalotF]]PetrelliA]]TraversaM&etal;Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.J Clin Endocrinol Metab200691813-8199. Sorkin JD, Muller DC, Fleg JL, et al. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005;28:2626–2632.SorkinJD]]MullerDC]]FlegJL&etal;The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature.Diabetes Care2005282626-263210. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397–405.DECODE Study Groupthe European Diabetes Epidemiology GroupGlucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.Arch Intern Med2001161397-40511. Levitan EB, Song Y, Ford ES, et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147–2155.LevitanEB]]SongY]]FordES&etal;Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies.Arch Intern Med20041642147-215512. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–494.ChiassonJL]]JosseRG]]GomisR&etal;STOP-NIDDM Trial Research GroupAcarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.JAMA2003290486-49413. Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83:1515–1522.JohnstonPS]]LebovitzHE]]ConiffRF&etal;Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.J Clin Endocrinol Metab1998831515-152214. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long- term studies. Eur Heart J 2004;25:10–16.HanefeldM]]CagatayM]]PetrowitschT&etal;Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long- term studies.Eur Heart J20042510-1615. Van de Laar FA, Lucassen PL. No evidence for a reduction of myocardial infarctions by acarbose. Eur Heart J 2004;25:1179; author reply 1179–1180.16. Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006;49:846–854.BonoraE]]CorraoG]]BagnardiV&etal;Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus.Diabetologia200649846-85417. Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 2001;24:1734–1738.ErlingerTP]]BrancatiFLPostchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes.Diabetes Care2001241734-173818. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881–885.MonnierL]]LapinskiH]]ColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).Diabetes Care200326881-88519. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007;77:280–285.WoerleHJ]]NeumannC]]ZschauS&etal;Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.Diabetes Res Clin Pract200777280-28520. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.UK Prospective Diabetes Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet1998352837-853
